Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: Age-relationship to safety and tolerability

Parkinsonism and Related Disorders

Volumn 19, Issue 1, 2013, Pages 37-42

  Oertel, Wolfgang ^a   LeWitt, Peter ^b,c   Giladi, Nir ^d   Ghys, Liesbet ^e   Grieger, Frank ^e   Boroojerdi, Babak ^e  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b HENRY FORD HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e UCB PHARMA   (Belgium)

Author keywords

Dopamine agonist; Elderly; Parkinson's disease; Rotigotine; Safety

Indexed keywords

PLACEBO; ROTIGOTINE;

ADULT; AGED; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; CONSTIPATION; CONTROLLED STUDY; CONTUSION; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; FALLING; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HALLUCINATION; HUMAN; HYPERTENSION; IMPULSE CONTROL DISORDER; INCIDENCE; INSOMNIA; JOINT SPRAIN; LIMB PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SPRAIN; TREMOR; URINARY TRACT INFECTION; URINE INCONTINENCE; VOMITING; XEROSTOMIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 84871492633     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.06.009     Document Type: Article

References (30)

1. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003, 157:1015-1022.
2. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5:525-535.
3. Antonini A., Tolosa E., Mizuno Y., Yamamoto M., Poewe W.H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009, 8:929-937.
4. Munchau A., Bhatia K.P. Pharmacological treatment of Parkinson's disease. Postgrad Med J 2000, 76:602-610.
5. Silver D. Impact of functional age on the use of dopamine agonists in patients with Parkinson disease. Neurologist 2006, 12:214-223.
6. Lewitt P.A. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008, 359:2468-2476.
7. Encarnacion E.V., Hauser R.A. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol 2008, 60:57-66.
8. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the American academy of neurology. Neurology 2002, 58:11-17.
9. Oertel W., Berardelli A., Bloem B., Bonuccelli U., Burn D., Deuschl G., et al. Review of the therapeutic management of Parkinson's disease. Eur handbook neurol management 2010, 217-236. Report of a joint task force of the European federation of neurological societies (EFNS) and the movement disorder society-European section (MDS-ES). [Chapter 14]: part I: early (uncomplicated) Parkinson's disease. M. Brainin, M. Barnes, N. Gilhus (Eds.).
10. Oertel W., Berardelli A., Bloem B., Bonuccelli U., Burn D., Deuschl G., et al. Review of the therapeutic management of Parkinson's disease. Eur handbook neurol management 2010, 237-267. Report of a joint task force of the European federation of neurological societies (EFNS) and the movement disorder society-European section (MDS-ES). [Chapter 15]: part II: late (complicated) Parkinson's disease. M. Brainin, M. Barnes, N. Gilhus (Eds.).
11. Simuni T., Lyons K.E., Pahwa R., Hauser R.A., Comella C., Elmer L., et al. Treatment of early Parkinson's disease. Part 1. Eur Neurol 2009, 61:193-205.
12. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007, 64:1242-1246.
13. Shulman L.M., Minagar A., Rabinstein A., Weiner W.J. The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov Disord 2000, 15:664-668.
14. Stowe R.L., Ives N.J., Clarke C., van Hilten J., Ferreira J., Hawker R.J., et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008, CD006564.
15. Biglan K.M., Holloway R.G., McDermott M.P., Richard I.H. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007, 69:187-195.
16. Fasano A., Guidubaldi A., De Nigris F., Bentivoglio A.R. Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older. J Am Geriatr Soc 2011, 59:2386-2387.
17. Rizos A., Koch I., Durner G., Martin A., Tluk S., Henriksen T., et al. Long acting dopamine agonists in clinical practice: a comparative multicentre European survey in young and old PD. Parkinsonism Relat Disord 2012, 18:S129-S130.
18. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005, 65:S3-S5.
19. Watts R.L., Jankovic J., Waters C., Rajput A., Boroojerdi B., Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68:272-276.
20. Giladi N., Boroojerdi B., Korczyn A.D., Burn D.J., Clarke C.E., Schapira A.H. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-2404.
21. Poewe W.H., Rascol O., Quinn N., Tolosa E., Oertel W.H., Martignoni E., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6:513-520.
22. LeWitt P.A., Lyons K.E., Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 2007, 68:1262-1267.
23. Jankovic J., Watts R.L., Martin W., Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007, 64:676-682.
24. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004, 18:733-746.
25. Bloem B.R., Beckley D.J., van Dijk J.G., Zwinderman A.H., Remler M.P., Roos R.A. Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease. Mov Disord 1996, 11:509-521.
26. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67:589-595.
27. Mitchell S.L., Sullivan E.A., Lipsitz L.A. Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol 1997, 54:1393-1398.
28. Mayeux R., Chen J., Mirabello E., Marder K., Bell K., Dooneief G., et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990, 40:1513-1517.
29. Saint-Cyr J.A., Taylor A.E., Lang A.E. Neuropsychological and psychiatricside effects in the treatment of Parkinson's disease. Neurology 1993, 43:S47-S52.
30. Giladi N., Weitzman N., Schreiber S., Shabtai H., Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007, 21:501-506.